Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen in Post-MI Patients with High Lp(a)
NCT04993664Withdrawn
- Sponsor
- University Medical Centre Ljubljana
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Randomised, double-blind trial in Hyperlipoproteinemia a comparing Pelacarsen Group with Placebo Group (2 arms). Primary endpoints: Ultrasound functional and morphological properties of the arterial wall at 6 months, Concentration of Lp(a) at 6 months and 1 more. Planned start Oct 2021; status: withdrawn.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT04993664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993664.